John Crowley, CEO of Novazyme Pharmaceuticals, the biotech startup company developing an orphan drug for the treatment of rare lysosomal storage disorder, from which his children suffer, must choose between the partnership and the ransom to have enough money and support to get the medicine market. In addition to this dilemma are questions regarding clinical trials Novazyme strategy, marketing, sales, production and pricing. This case introduces students to the process of drug approval by the FDA and government-supported financial incentives to develop drugs for small patient populations. Also provides insights into the nature of the strategic relationship in the biotechnology and pharmaceutical industries. "Hide
by Richard Bohmer, Bradley Campbell Source: Harvard Business School 24 pages. Publication Date: October 22, 2002. Prod. #: 603048-PDF-ENG
Related Case Solutions & Analyses:
The Drivers of Greenwashing
China s Challenge to Feed Its People
Bank of America: Mobile Banking
Note on the FDReview Process for Medical Devices
A Big (Double) Deal: Anadarko’s Acquisition of Kerr-McGee and Western Gas Resources
STRATEGIES FOR DEVELOPING VALUE ADDED TAX IN SAUDI ARABIA
Keirsey Style Personality – Self Assessment
PROJECT ENERGY GEL
Metapath Case
Angus Cartwright Case Memorandum
